Polish Journal of Pathology
1/2025 vol. 76
Original paper

Crosstalk between OPG/RANKL/RANK in bone marrow mesenchymal stem cells and Wnt/b-catenin pathway in prostate cancer cells regulates bone metastasis of prostate cancer

Shihua Ye 1
,
Qiongyun Lin 1
,
Meihua Deng 1
,
Shulong Huang 1
,
Changlin Mao 1
,
Jiabin Zhang 1
,
Wuming Zhan 1
,
Guangbing Chen 1
  1. Department of Urology, Mindong Hospital Affiliated to Fujian Medical University, Fuan City, Ninde, Fujian, 355000, China
Pol J Pathol 2025; 76 (1): 25-37
DOI: https://doi.org/10.5114/pjp.2025.150029
Data publikacji online: 2025/04/28
Article files
03153 Crosstalk between.pdf 03153 Crosstalk between supl.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
1. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med 2018; 8: a030361.
2. Sayyid RK, Benton JZ, Reed WC, et al. Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis. World J Urol 2023; 41: 93-99.
3. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583.
4. Mazzone E, Preisser F, Nazzani S, et al. Location of metastases in contemporary prostate cancer patients affects cancer-specific mortality. Clin Genitourin Cancer 2018; 16: 376-384 e1.
5. Baldessari C, Pipitone S, Molinaro E, et al. Bone metastases and health in prostate cancer: from pathophysiology to clinical implications. Cancers (Basel) 2023; 15: 1518.
6. Wong SK, Mohamad NV, Giaze TR, Chin KY, Mohamed N, Ima-Nirwana S. Prostate cancer and bone metastases: the underlying mechanisms. Int J Mol Sci 2019; 20: 2587.
7. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4: 801-811.
8. Zhang Y, Liang J, Liu P, Wang Q, Liu L, Zhao H. The RANK/RANKL/OPG system and tumor bone metastasis: potential mechanisms and therapeutic strategies. Front Endocrinol (Lausanne) 2022; 13: 1063815.
9. Gao Q, Wang L, Wang S, Huang B, Jing Y, Su J. Bone marrow mesenchymal stromal cells: identification, classification, and differentiation. Front Cell Dev Biol 2021; 9: 787118.
10. Ridge SM, Bhattacharyya D, Dervan E, et al. Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumourigenic ‘activated’ state that enhances prostate cancer cell migration. Int J Cancer 2018; 142: 2056-2067.
11. Borghese C, Casagrande N, Pivetta E, et al. Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. Oncotarget 2017; 8: 42926-42938.
12. Bisson I, DM Prowse. WNT signaling regulates self-renewal and differentiation of ,rostate cancer cells with stem cell characteristics. Cell Res 2009; 19: 683-697.
13. Park M, Cho YJ, Kim B, et al. RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway. Sci Rep 2021; 11: 12186.
14. Patel S, Alam A, Pant R, Chattopadhyay S. Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights. Front Immunol 2019; 10: 2872.
15. Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Molecular targets for epigenetic therapy of cancer. Curr Pharm Biotechnol 2009; 10: 161-165.
16. Xu Y, Li W, Lin S, Liu B, Wu P, Li L. Fibroblast diversity and plasticity in the tumor microenvironment: roles in immunity and relevant therapies. Cell Commun Signal 2023; 21: 234.
17. Prantl L, Muehlberg F, Navone NM, et al. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 2010; 70: 1709-1715.
18. Ye H, Cheng J, Tang Y, et al. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest 2012; 30: 513-518.
19. Guo Q, Jin Y, Chen X, et al. NF-kappaB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther 2024; 9: 53.
20. Ming J, Cronin SJF, Penninger JM. Targeting the RANKL/RANK/OPG axis for cancer therapy. Front Oncol 2020; 10: 1283.
21. Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer 2017; 16: 31.
22. Lee MA, Park JH, Rhyu SY, et al. Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer 2014; 14: 125.
23. Huang D, Du X. Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol 2008; 14: 1823-1827.
24. Rao C, Lin SL, Ruan WJ, Wen H, Wu DJ, Deng H. High expression of IGFBP7 in fibroblasts induced by colorectal cancer cells is co-regulated by TGF-beta and Wnt signaling in a Smad2/3-Dvl2/3-dependent manner. PLoS One 2014; 9: e85340.
25. Jridi I, Canté-Barrett K, Pike-Overzet K, Staal FJT. Inflammation and Wnt signaling: target for immunomodulatory therapy? Front Cell Dev Biol 2020; 8: 615131.
Copyright: © 2025 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications